New online calculator launched to determine risk of spread of melanoma
15 June 2020
Clinicians around the world now have access to a new online calculator that predicts the risk that a patient’s primary melanoma has spread to nearby lymph nodes.
For patients recently diagnosed with melanoma, one of the first hurdles is to find out whether the melanoma cells have spread. To do this, clinicians will biopsy the first lymph node (known as the “sentinel” node) to see if melanoma cells are present, indicating that spread to it has occurred. If it has, it greatly increases the likelihood that it has spread further. This information in turn, helps determine the patient’s best treatment plan.
Dr Alexander Varey and Associate Professor Serigne Lo from Melanoma Institute Australia, whose team developed the calculator based on research published today in the Journal of Clinical Oncology, said it has the potential to better identify melanoma patients who are most likely to benefit from a sentinel node biopsy, as well as those least likely to benefit.
‘For us, one of the big questions was, can we better predict which patients will be at significant risk of having their cancer spread to their lymph nodes?’ said Dr Varey. ‘That’s what this calculator aims to do.
‘The calculator takes into account five pieces of basic information about the melanoma and the patient’s age to determine the patient’s individual risk of the cancer having spread to their lymph nodes.
‘This means that patients deemed at low risk of disease spread can potentially avoid having a sentinel node biopsy, which sometimes has complications and usually requires a general anaesthetic.’
Current treatment guidelines recommend that if a patient has a tumour with a particular set of parameters – mainly tumours that are slightly thicker or ulcerated – then removal and examination of the sentinel node should be considered. However, these guidelines are not tailored to individual patients and don’t take into account important information including the age of the patient. Younger age is known to be one of the most important risk factors for melanoma spreading to lymph nodes.
Supported by a Sydney Health Partners grant, the MIA team used established international calculators as a starting point. The research team tailored them to Australian demographics using patient data from Melanoma Institute Australia’s extensive database, which has been built up over a 50-year period. The team then built a new calculator to include additional patient parameters that increased its reliability and showed it provided considerably more accurate predictions than were previously available.
The calculator has been trialed at sites including Royal Prince Alfred, Royal North Shore and Westmead Hospitals with enthusiastic responses from clinicians and their patients.
‘The calculator enables clinicians to have better informed discussions with their patients based on each individual’s percentage risk, rather than a few simplistic criteria that only approximate the risk of disease spread to the lymph nodes,’ said MIA Co-Medical Directors, Professor Richard Scolyer and Professor Georgina Long AO.
‘The main benefit of the calculator is likely to be for those deemed to be at low risk of disease spread, who can safely forgo a sentinel node biopsy. This is of benefit particularly to older patients who are less likely to have melanoma spread to their lymph nodes, but who are at increased risk of complications from extra surgery and general anaesthesia.’
The Sentinel Node Biopsy Risk Calculator is available for clinician use here: www.melanomarisk.org.au
An improved risk-prediction calculator for sentinel node positivity in melanoma patients: the MIA nomogram.
Serigne N Lo, Jiawen Ma, Richard A Scolyer, Lauren E Haydu, Jonathan R Stretch, Robyn PM Saw, Omgo E Nieweg, Kerwin F Shannon, Andrew J Spillane, Sydney Ch’ng, Graham J Mann, Jeffrey E Gershenwald, John F Thompson, Alexander HR Varey.
Published in: Journal of Clinical Oncology
Our first Global Melanoma Research Report shares selected research from around the world and here at MIA that is making a difference to the lives of melanoma patients now and in the future.
After 18 years as Director of the Sydney Melanoma Unit and then Executive Director of Melanoma Institute Australia, Professor John Thompson AO will step down from the position at the end of 2016.
Australian melanoma clinical practice guidelines have been published on a wiki platform for the first time as researchers try to keep up to date with emerging evidence.
Carole Renouf, CEO of Melanoma Institute Australia is asking young Australians who have been affected by melanoma to share their experiences with her.
Melanoma Institute Australia CEO Carole Renouf wants to make sure Aussies remember to take care of our skin as the festive season draws closer and we spend more time in the sun.
Can an individual’s risk factors for melanoma be used to tailor skin self-examinations and surveillance programs?
Prof Georgina Long has been appointed President-Elect Society for Melanoma Research (SMR).
The Australasian Melanoma Conference is bringing together some of the world's leading researchers and clinicians.
Best practice guidelines for melanoma care have gone digital with the first-ever online guidelines developed to adapt to the rapid change in clinical management.
Congratulations are in order for two of our talented researchers.
Professor Richard Scolyer will be sharing his expertise on melanoma pathology at the upcoming Australasian Melanoma Conference. Here he discusses what he'll be presenting on.
Researchers at MIA have established a High Risk Clinic to monitor people at very high risk of developing melanoma.
A generous donation has enabled a medical oncologist from Portugal to learn from the best in the world at MIA.
MIA is hosting a conference to bring together greats minds in melanoma research that will make a difference to the lives of melanoma patients
Meet Michelle, our Translational Research Officer whose role is to connect the clinics to the lab by ensuring patient blood and tissue samples are documented and carefully stored in our BioSpecimen Bank.
Dr James Wilmott says his Wildfire Award will help expand research into treatment options for people with mucosal melanoma, a rare but deadly form of skin cancer.
Following the recent hype around immunotherapies in cancer, CEO Carole Renouf shares the greatest story never told… resistance… and what MIA is doing to address it.
A/Prof Wargo discusses the research she will be presenting as a keynote speaker at the upcoming Australasian Melanoma Conference.
Dr James Wilmott has been awarded the Wildfire award at this year's Cancer Institute NSW's Premier Awards for Outstanding Cancer Research.
The community has responded generously to our recent appeal to fund a specialised nursing position in an exciting new clinical trial.